Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITPNew data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-upPrimary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHDTop-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHDPhase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHDPresenters:Hanny Al-Samkari, MDInstructorDepartment of MedicineHarvard Medical SchoolAttending Hematologist and Clinical InvestigatorDivision of Hematology OncologyMassachusetts General HospitalBoston, MassachusettsSujit Sheth, MDProfessorDepartment of PediatricsWeill Cornell MedicineNew York, New YorkMark A. Schroeder, MDAssociate Professor of MedicineDivision of OncologyDepartment of MedicineWashington University School of Medicine in St LouisSt Louis, MissouriContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology. Link to full program, including downloadable slidesets, and on-demand Webcasts:http://bit.ly/3tyQ9nG

There are no comments yet.

Please log in to write the first comment.